Table 2. Characteristics of treatment.
| Characteristics | No. of patients (%) | |||||
|---|---|---|---|---|---|---|
| Chemotherapy | Neoadjuvant CT only | 3 (4.2) | ||||
| cCRT | 47 (66.2) | |||||
| Neoadjuvant + cCRT | 7 (9.9) | |||||
| No CT | 14 (19.7) | |||||
| Number of cCRT cycles | ≤ 4 | 40 (56.3) | ||||
| ≥ 5 | 24 (33.8) | |||||
| Unknown | 7 (9.9) | |||||
| Radiotherapy: technique | 2DCRT | 19 (26.8) | ||||
| 3DCRT | 35 (49.3) | |||||
| IMRT | 5 (7.0) | |||||
| Not detailed | 12 (16.9) | |||||
| Radiotherapy: fields | Pelvic | 48 (67.6) | ||||
| Pelvic + paraaortic | 23 (32.4) | |||||
| Sequential radiation boost | Parametrium | 12 (16.9) | ||||
| Pelvic nodes | 18 (25.4) | |||||
| Para-aortic nodes | 9 (12.7) | |||||
| Brachytherapy | LDR | 33 (46.5) | ||||
| PDR | 31 (43.7) | |||||
| No BT | 7 (10) | |||||
| OTT (from the start of RT to the end of BT, n = 64) | ≤ 55 days | 38 (59.4) | ||||
| > 55 days | 26 (40.6) | |||||
| Median (range) | 54 days (42–143) | |||||
| Dosimetric Parameters | Mean ± SD | N available | ||||
| Radiotherapy | Pelvic dose | 44.7 ± 3.1 | 71 | |||
| Brachytherapy | Points A dose (Gyα/β10) | 71.1 ± 9.2 | 45 | |||
| TRAK (cGy.h−1.m−1) | 2.0 ± 0.4 | 64 | ||||
| V15Gyα/β3 (cm3) | 270.2 ± 78.70 | 63 | ||||
| HR-CTV | Volume (cm3) | 48.9 ± 27.6 | 31 | |||
| D90 (Gyα/β10) | 72.6 ± 9.7 | 30 | ||||
| IR-CTV | Volume (cm3) | 108.5 ± 50.6 | 31 | |||
| D90 (Gyα/β10) | 63.1 ± 5.0 | 30 | ||||
| Bladder | D2cc (Gyα/β3) | 74.7 ± 6.5 | 30 | |||
| ICRU (Gyα/β3) | 72.0 ± 13.0 | 57 | ||||
| Rectum | D2cc (Gyα/β3) | 66.1 ± 5.9 | 30 | |||
| ICRU (Gyα/β3) | 74.5 ± 13.9 | 58 | ||||
| Sigmoid | D2cc (Gyα/β3) | 57.8 ± 6.7 | 30 | |||
Abbreviations: cCRT: concurrent chemoradiation; TRAK: total reference air kerma; ICRU: International Commission Radiation Units: HR-CTV: high-risk clinical target volume; IR: intermediate-risk clinical target volume: OTT: overall treatment time; RT: radiation therapy; LDR: low dose rate; PDR: pulse dose rate; BT: brachytherapy.